|
Revatio and PAH / PPH
This website was created to provide you with news about Revatio (Sildenafil), a drug used to treat people who have been diagnosed with Pulmonary Arterial Hypertension (PAH) formally referred to as Primary Pulmonary Hypertension (PPH). We also have information about PAH / PPH and its symptoms, new prescription medications such as Revatio, Tracleer Flolan and Remodulin, and other alternative methods of PAH / PPH treatment. In addition, we have a Free Information Packet on Revatio, other medications and PAH / PPH treatments.
The Company Behind Revatio
Pfizer spent six years testing Revatio for PAH / PPH. The transforming of a compound for erectile dysfunction into a treatment for PAH / PPH isn't such a stretch, because both Viagra and Revatio work by improving blood flow by relaxing blood vessels. After all, when Pfizer started studying the drug that eventually became Viagra, the goal was to find a new blood-pressure treatment.
Although Pfizer says PAH affects about 100,000 people worldwide, the market is crowded with treatments and experimental products. The other PAH pill on the market is Tracleer from the Swiss company Actelion.
About 100,000 people in the USA and Europe are afflicted with either idiopathic pulmonary arterial hypertension (IPAH) or forms of the disease that are secondary to other conditions. The most common symptom of pulmonary arterial hypertension, which is dyspnea (breathlessness) is often misdiagnosed because it can be caused by a number of other diseases. Statistics show the average time for correct diagnosis is two to three years. Revatio marks the second pill approved for the rare condition known as PAH / PPH . The disease is characterized by dangerously high blood pressure in blood vessels leading from the heart to the lungs. Without treatment, patients could die within three years of diagnosis. Pfizer says. Symptoms include fatigue, dizziness and difficulty breathing.
|
